journal article·2025-11-19

Cross-Linked Lipoic Acid Trisulfide Nanoparticles: Revisiting H 2 S Intervention as a Stand-alone Modality for Cancer Therapy

Hao Guo, Zhong Shao, Gang Wang, Yangyang Cheng, Shiyong Zhang

Nano Letters· Volume 25· Issue 46
Publisher page

Abstract

Despite the pleiotropic anticancer potential of the endogenous gasotransmitter hydrogen sulfide (H 2 S), achieving sustained and adequate intratumoral H 2 S supply remains a persistent challenge, hindering its advancement as a stand-alone therapeutic modality. Herein, we introduce cross-linked lipoic acid trisulfide nanoparticles (cLATN) that integrate both the H 2 S donor and transporter within a single precursor, wherein each unit theoretically yields one molecule of H 2 S, enabling stoichiometric H 2 S loading. cLATN effectively enter tumor cells via thiol-mediated uptake and are depolymerized by glutathione to trigger sufficient H 2 S release in tumor tissues for more than 48 h, far surpassing current H 2 S-based anticancer agents, which generally persist for only a few hours. Therapeutically, cLATN achieve an impressive tumor inhibition rate of 83% with favorable biocompatibility, far exceeding the clinical agent doxorubicin in both efficacy and safety. This work affirms its potential for cancer treatment, renewing interest in positioning H 2 S intervention as a stand-alone modality toward broader clinics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Sulfur Compounds in Biology · Metalloenzymes and iron-sulfur proteins · Enzyme function and inhibition

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Biomedical Engineering and National Engineering Research Center for Biomaterials

Sichuan University

Funding

National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.1038/s41420-024-01868-w10.1038/s41420-024-01868-w ↗
2. 10.1038/s41392-025-02231-w10.1038/s41392-025-02231-w ↗
3. 10.1038/nrd242510.1038/nrd2425 ↗
4. 10.1096/fj.02-0211hyp10.1096/fj.02-0211hyp ↗
5. 10.1111/bph.1277310.1111/bph.12773 ↗
6. 10.1021/jacs.2c0766910.1021/jacs.2c07669 ↗
7. 10.3390/molecules2711338910.3390/molecules27113389 ↗
8. 10.1016/j.redox.2020.10156410.1016/j.redox.2020.101564 ↗
9. 10.1371/journal.pone.012378110.1371/journal.pone.0123781 ↗
10. 10.1146/annurev-pharmtox-010510-10050510.1146/annurev-pharmtox-010510-100505 ↗
11. 10.1111/bph.1236810.1111/bph.12368 ↗
12. 10.1139/o82-07610.1139/o82-076 ↗
13. 10.3390/cells1002022010.3390/cells10020220 ↗
14. 10.1371/journal.pone.003456210.1371/journal.pone.0034562 ↗
15. 10.1021/ja508063s10.1021/ja508063s ↗
16. 10.1136/gutjnl-2011-30072110.1136/gutjnl-2011-300721 ↗
17. 10.1002/adhm.20210198410.1002/adhm.202101984 ↗
18. 10.1089/ars.2017.705810.1089/ars.2017.7058 ↗
19. 10.1038/nrd.2015.110.1038/nrd.2015.1 ↗
20. 10.1038/nrd443310.1038/nrd4433 ↗
21. 10.1016/j.ccr.2025.21674610.1016/j.ccr.2025.216746 ↗
22. 10.1002/adfm.20250738410.1002/adfm.202507384 ↗
23. 10.1161/CIRCRESAHA.118.31113410.1161/CIRCRESAHA.118.311134 ↗
24. 10.1038/s41467-019-14132-y10.1038/s41467-019-14132-y ↗
25. 10.1016/j.jconrel.2022.10.05510.1016/j.jconrel.2022.10.055 ↗
26. 10.1016/j.bioactmat.2022.03.04310.1016/j.bioactmat.2022.03.043 ↗
27. 10.1002/cbic.20240081710.1002/cbic.202400817 ↗
28. 10.1038/nm106110.1038/nm1061 ↗
29. 10.1021/jacs.8b0658410.1021/jacs.8b06584 ↗
30. 10.1021/jacsau.1c0012810.1021/jacsau.1c00128 ↗
31. 10.1038/s41467-024-48097-410.1038/s41467-024-48097-4 ↗
32. 10.1021/jacs.3c0323910.1021/jacs.3c03239 ↗
33. 10.1021/acs.orglett.7b0085810.1021/acs.orglett.7b00858 ↗
34. 10.1016/j.xcrm.2024.10143210.1016/j.xcrm.2024.101432 ↗
35. 10.1038/s41467-023-38601-710.1038/s41467-023-38601-7 ↗
36. 10.1021/jo00323a01910.1021/jo00323a019 ↗
37. 10.1093/nsr/nwaa03410.1093/nsr/nwaa034 ↗
38. 10.1002/med.2143310.1002/med.21433 ↗
39. 10.1126/sciadv.abc172510.1126/sciadv.abc1725 ↗
40. 10.1021/jacs.3c1191410.1021/jacs.3c11914 ↗
41. 10.1002/adma.20170234210.1002/adma.201702342 ↗